Microdosing psychedelics delivers a measurable lift in mood and focus, but only on the day you take it. By the next morning, the benefits have evaporated.
That’s the core finding from a new international study tracking more than 1,400 people who microdose LSD or psilocybin. Researchers at the University of British Columbia Okanagan analyzed daily self-reports from participants across 49 countries, all logging their mental state each morning through the Microdose.me project.
On dosing days, people consistently reported higher scores across six measures: wellbeing, productivity, creativity, connectedness, contemplation, and focus. The improvements were significant and showed up across the board. But here’s the catch: those gains didn’t carry over to the following day, even though many microdosers space out their doses specifically hoping for lingering effects.
Dr. Michelle St. Pierre, the post-doctoral psychology researcher who led the study, says the timing is clarifying. People feel better on the day they dose, period.
“Microdosing appears to lift mood and mental functioning on the days it’s practiced, but not necessarily beyond that.”
The study design took advantage of how people actually microdose in the wild. Most follow a schedule that alternates dosing days with breaks, partly to avoid building tolerance and partly to see if benefits persist. That built-in contrast let researchers compare the same person on drug days versus off days.
Real Benefits or Expectation?
The immediate question: are these genuine pharmacological effects, or are people just feeling better because they expect to? The study can’t definitively answer that. It’s observational, meaning participants knew when they were dosing, and expectancy effects with psychedelics are notoriously strong.
Still, the consistency is striking. The researchers found the same pattern across nearly every subgroup they examined: men and women, people with and without mental health histories, LSD users versus psilocybin users. The day-of boost showed up regardless of background or substance choice.
There was one exception. Participants who’d previously taken full psychedelic doses, the kind that produce hours-long trips, reported slightly bigger creativity gains on their microdosing days compared to psychedelic-naive users. That’s a small but interesting wrinkle.
St. Pierre thinks it might mean microdosing builds on changes already triggered by larger doses, though she’s careful to note that’s speculative. The data hints at a connection but doesn’t prove it.
What This Means for Users
For the growing number of people experimenting with microdosing, often outside legal frameworks, the findings offer both validation and limitation. Yes, you probably do feel sharper and more connected on dosing days. No, you’re not getting a sustained upgrade to your baseline functioning.
The study involved more than 1,435 participants self-reporting through a phone app every morning, making it the largest real-world dataset on microdosing to date. That scale matters because it moves past anecdotal Reddit threads and gets at actual patterns.
But it’s still self-reported data from people who chose to microdose, which means selection bias and placebo effects are baked in. The next step, according to St. Pierre, is rigorous placebo-controlled trials that can isolate the chemical effects from expectations.
“We need future research designed specifically to test whether microdosing can amplify or extend the impacts of larger-dose psychedelic experiences.”
That question about amplification is particularly relevant as psychedelic therapy gains traction for depression and PTSD. If microdosing can extend or reactivate benefits from therapeutic trips, that changes the conversation about how these substances might be used clinically.
For now, the takeaway is straightforward: microdosing seems to work, but only while it’s active in your system. The idea of microdosing your way to permanent cognitive enhancement doesn’t hold up here. You get a boost, it fades, and you’re back to baseline by tomorrow.
Psychopharmacology: 10.1007/s00213-025-06913-9
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.